More search options
Basket icon
No items
Basket icon

Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Compact case
Case
-
Reference no. IMD-7-2317
Subject category: Entrepreneurship
Authors: Benoit Leleux (International Institute for Management Development (IMD)); Jennifer Jordan (International Institute for Management Development (IMD)); Omar Toulan (International Institute for Management Development (IMD)); Beverley Lennox (International Institute for Management Development (IMD))
Published by: International Institute for Management Development (IMD)
Originally published in: 2022
Version: 28.01.2022
Length: 5 pages
Data source: Field research
Topics: Entrepreneurship; Leadership; Biopharmaceutical; Initial public offering; Clinical trial; Funding; Acquisition; Finance
Share a link: https://casecent.re/p/182038
| No reviews for this item
This product has not been used yet
View our pricing guide or login to see prices.

Abstract

This is part of a case series. The B case describes the events - including the offers and the negotiation - leading up to Sundown's acquisition of Cyna for USD40.50 per share in cash or USD624 million (approximately CAD841 million) - a 120% premium over the closing price of just over USD18 a share before the deal was announced. The case also brings the reader up to date on the turns Anthony's life has taken since the acquisition and some of the exciting ventures in which he is now involved.

Time period

The events covered by this case took place in 2002-2016.

Geographical setting

Country:
Canada

Featured company

Cyna Pharma (Disguised)
Turnover:
USD 624 million
Industry:
Biopharmaceuticals
Case
-
Reference no. IMD-7-2316
Subject category: Entrepreneurship
Authors: Benoit Leleux (International Institute for Management Development (IMD)); Jennifer Jordan (International Institute for Management Development (IMD)); Omar Toulan (International Institute for Management Development (IMD)); Beverley Lennox (International Institute for Management Development (IMD))
Published by: International Institute for Management Development (IMD)
Originally published in: 2022
Version: 26.01.2022
Length: 17 pages
Data source: Field research
Topics: Entrepreneurship; Leadership; Biopharmaceutical; Initial public offering; Clinical trial; Funding; Acquisition; Finance
View full details

About

Abstract

This is part of a case series. The B case describes the events - including the offers and the negotiation - leading up to Sundown's acquisition of Cyna for USD40.50 per share in cash or USD624 million (approximately CAD841 million) - a 120% premium over the closing price of just over USD18 a share before the deal was announced. The case also brings the reader up to date on the turns Anthony's life has taken since the acquisition and some of the exciting ventures in which he is now involved.

Settings

Time period

The events covered by this case took place in 2002-2016.

Geographical setting

Country:
Canada

Featured company

Cyna Pharma (Disguised)
Turnover:
USD 624 million
Industry:
Biopharmaceuticals

Related

Case
-
Reference no. IMD-7-2316
Subject category: Entrepreneurship
Authors: Benoit Leleux (International Institute for Management Development (IMD)); Jennifer Jordan (International Institute for Management Development (IMD)); Omar Toulan (International Institute for Management Development (IMD)); Beverley Lennox (International Institute for Management Development (IMD))
Published by: International Institute for Management Development (IMD)
Originally published in: 2022
Version: 26.01.2022
Length: 17 pages
Data source: Field research
Topics: Entrepreneurship; Leadership; Biopharmaceutical; Initial public offering; Clinical trial; Funding; Acquisition; Finance
View full details